New drug combo tested to fight tough ovarian cancers
NCT ID NCT03249142
Summary
This study tested whether adding immunotherapy drugs to standard chemotherapy before surgery is safe and feasible for patients with advanced ovarian cancer. The trial involved 69 women with newly diagnosed, advanced ovarian, fallopian tube, or primary peritoneal cancer who were not candidates for immediate surgery. Researchers compared two approaches: chemotherapy with one immunotherapy drug versus chemotherapy with two immunotherapy drugs, followed by surgery and potentially more treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Eugene Marquis
Rennes, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Groupe confluent
Nantes, 44202, France
-
Gustave Roussy
Villejuif, France
-
HEGP
Paris, France
-
Hôpital Cochin
Paris, France
-
ICM Val d'Aurelle
Montpellier, France
-
Institut Bergonié
Bordeaux, France
-
Institut René Godinot
Reims, France
-
Institut Ste Catherine
Avignon, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Conditions
Explore the condition pages connected to this study.